Recently, two tumor clinical research achievements, led by Jiangsu Provincial People's Hospital and collaboratively conducted by Nanjing Yuzhong Pharmaceutical, have been officially published in the international academic journals "Translational Oncology" and "Medicine" respectively. Dr. Li Zhengqi, the chairman, participated deeply in the relevant scientific research as a professional consultant for the project, providing important professional support for the smooth implementation and publication of the two studies.

This scientific research collaboration adheres to the model of academic leadership by clinical teams, relying on the professional wisdom of clinical experts and combining the professional strengths of GCP and clinical project management to achieve the organic integration of clinical research and standardized scientific research management. The two studies explore the directions of tumor immune microenvironment of lung adenocarcinoma and efficacy prediction of locally advanced rectal cancer, respectively, integrating medical data analysis, radiomics, and multi-omics technologies to provide new research evidence for individualized diagnosis and treatment of cancer patients.

《CTSB-positive tumor-associated macrophages shape prognosis and therapeutic response in lungadenocarcinoma》Published《Translational Oncology》（2026，Volume65，Article102671）。

Dr. Li Zhengqi has long been deeply involved in the fields of drug regulation and clinical drug trials, actively participating in the construction of domestic clinical trial regulatory systems. He possesses both a macro-level industry perspective and hands-on experience in clinical trial institution management, project full-process control, quality and risk management. During the advancement of the two oncology research projects, he adhered to the GCP (Good Clinical Practice) requirements, providing professional consultative advice to clinical researchers from multiple dimensions, including the scientific nature of clinical research protocols, project implementation process design, data management strategies, and quality control points. He assisted the research team in clarifying work ideas, refining research implementation details, and providing professional guidance on the standardized presentation of scientific research results. Additionally, Dr. Li Zhengqi co-authored a paper in Medicine, reflecting his deep involvement in the scientific research project and collaboration with the clinical team to achieve academic output.

"Efficacy of HALP combined with T2-weighted MRI radiomics in predicting pathological complete response and overall survival in patients with rectal cancer after neoadjuvant chemoradiotherapy" was published in Medicine (2026, Vol. 105, No.37, e50554).

Dr. Li Zhengqi will continue to leverage his professional expertise in GCP system construction, clinical trial quality control, and clinical research consultation. He will continue to collaborate with clinical medical institutions and experts to facilitate the implementation of more high-quality clinical studies and promote the translation of clinical research outcomes. Relying on Dr. Li Zhengqi and the clinical research team's solid GCP professional capabilities, Licheng Pharmaceutical will continue to promote drug clinical research in a standardized and efficient manner. Focusing on unmet clinical needs, the company will accelerate the development and implementation of high-quality drugs, so that more effective medications can benefit a wide range of patients.